Letter to the Editor. Therapy of mental disorders with the use of transcranial magnetic stimulation and the limitations of the method. Commentary on the article Transcranial magnetic stimulation (TMS) in treatment of psychiatric disorders – review of current studies
Psychiatria Polska · 2023
DOI: 10.12740/pp/155103 ↗Kurz gefasst
Leserbrief in der Zeitschrift Psychiatria Polska, 2023. Verfasst von Justyna Hobot. Beteiligte Einrichtung: Laboratorium Badań Świadomości, Instytut Psychologii i Centrum Badań Mózgu, Uniwersytet Jagielloński, Kraków, Polska. Hauptthemen laut MEDLINE: Mental Disorders, Transcranial Magnetic Stimulation. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
bez streszczenia
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratorium Badań Świadomości, Instytut Psychologii i Centrum Badań Mózgu, Uniwersytet Jagielloński, Kraków, Polska.
Zitieren
APA
Hobot, J. (2023). Letter to the Editor. Therapy of mental disorders with the use of transcranial magnetic stimulation and the limitations of the method. Commentary on the article Transcranial magnetic stimulation (TMS) in treatment of psychiatric disorders – review of current studies. Psychiatria Polska. https://doi.org/10.12740/pp/155103
Vancouver
Hobot J. Letter to the Editor. Therapy of mental disorders with the use of transcranial magnetic stimulation and the limitations of the method. Commentary on the article Transcranial magnetic stimulation (TMS) in treatment of psychiatric disorders – review of current studies. Psychiatria Polska. 2023. doi:10.12740/pp/155103
BibTeX
@article{Hobot2023,
author = {Hobot, Justyna},
title = {Letter to the Editor. Therapy of mental disorders with the use of transcranial magnetic stimulation and the limitations of the method. Commentary on the article Transcranial magnetic stimulation (TMS) in treatment of psychiatric disorders – review of current studies},
journal = {Psychiatria Polska},
year = {2023},
doi = {10.12740/pp/155103}
}
EUVIMED